Genmab — August 2018
-
-
What data is expected from Alcyone?
-
No data expected - but approval in EU
-
Sådan kan det gå Henrik. Tak for opfølgningen
-
Alt under 90 % er uacceptabelt
-
Var der noget om det stoppede forsøg?
-
@Bulder Other Highlights
•Recruitment completed in Phase III relapsing MS studies of subcutaneous ofatumumab
•New strategic partnership with Immatics
•Expansion phase started in HuMax-AXL-ADC Phase I/II study in solid tumors
•First patients dosed in HexaBody-DR5/DR5 study and DuoBody-CD3xCD20 study
•Improved revenue by DKK 167M vs. first six months of 2017 -
Bare for at skære det ud i pap.
-
Hvor sikre er vi egentlig på gode MAIA data ala Alcyone? Spørger fordi det er den klart største kurspåvirkende nyhed i nærmeste fremtid.
-
Er der reelt mulighed for skuffelse? Vi vil blive straffet ekstremt meget,
hvis det bliver tilfældet. Turde ikke engang tænke tanken. -
Vi steg jo ret pænt ved Alcyone data i august sidste år. Tror det var omkring 10%.
-
@Plimsoller just repeated that the study was only stopped in non-small cell lung cancer, but that many studies continued in MM and we will hear additional new combinations hopefully from abstracts at ASH
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind